AR097732A1 - Composiciones que comprenden poblaciones heterogéneas de proteínas recombinantes humanas de factor xa de coagulación - Google Patents

Composiciones que comprenden poblaciones heterogéneas de proteínas recombinantes humanas de factor xa de coagulación

Info

Publication number
AR097732A1
AR097732A1 ARP140103512A ARP140103512A AR097732A1 AR 097732 A1 AR097732 A1 AR 097732A1 AR P140103512 A ARP140103512 A AR P140103512A AR P140103512 A ARP140103512 A AR P140103512A AR 097732 A1 AR097732 A1 AR 097732A1
Authority
AR
Argentina
Prior art keywords
compositions
factor
heterogenic
populations
coagulation
Prior art date
Application number
ARP140103512A
Other languages
English (en)
Spanish (es)
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer filed Critical Pfizer
Publication of AR097732A1 publication Critical patent/AR097732A1/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46Hydrolases (3)
    • A61K38/48Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/482Serine endopeptidases (3.4.21)
    • A61K38/4846Factor VII (3.4.21.21); Factor IX (3.4.21.22); Factor Xa (3.4.21.6); Factor XI (3.4.21.27); Factor XII (3.4.21.38)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/36Blood coagulation or fibrinolysis factors
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14Hydrolases (3)
    • C12N9/48Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424Serine endopeptidases (3.4.21)
    • C12N9/6432Coagulation factor Xa (3.4.21.6)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Zoology (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Wood Science & Technology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Analytical Chemistry (AREA)
  • Biophysics (AREA)
  • Water Supply & Treatment (AREA)
  • Toxicology (AREA)
ARP140103512A 2013-09-24 2014-09-23 Composiciones que comprenden poblaciones heterogéneas de proteínas recombinantes humanas de factor xa de coagulación AR097732A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201361881834P 2013-09-24 2013-09-24

Publications (1)

Publication Number Publication Date
AR097732A1 true AR097732A1 (es) 2016-04-13

Family

ID=51844797

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP140103512A AR097732A1 (es) 2013-09-24 2014-09-23 Composiciones que comprenden poblaciones heterogéneas de proteínas recombinantes humanas de factor xa de coagulación

Country Status (19)

Country Link
US (3) US9757434B2 (enExample)
EP (1) EP3049434A1 (enExample)
JP (1) JP6429885B2 (enExample)
KR (1) KR101988705B1 (enExample)
CN (2) CN105579468A (enExample)
AR (1) AR097732A1 (enExample)
AU (1) AU2014326257B2 (enExample)
BR (1) BR112016005899A8 (enExample)
CA (1) CA2924981C (enExample)
HK (1) HK1218760A1 (enExample)
IL (2) IL244258A0 (enExample)
MX (1) MX373466B (enExample)
MY (1) MY173548A (enExample)
PE (1) PE20160877A1 (enExample)
RU (1) RU2648144C2 (enExample)
SA (1) SA516370751B1 (enExample)
SG (1) SG11201601221XA (enExample)
TW (1) TWI631134B (enExample)
WO (1) WO2015044836A1 (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20150343034A1 (en) 2013-01-31 2015-12-03 Pfizer Inc. Compositions and methods for counteracting factor xa inhibition
CN105579468A (zh) 2013-09-24 2016-05-11 辉瑞大药厂 包含重组人凝血因子Xa蛋白的异质性群体的组合物
ES2875538T3 (es) 2016-06-17 2021-11-10 Alexion Pharma Inc Preparación de derivados del factor Xa
EP3722418A1 (en) * 2019-04-08 2020-10-14 AB Enzymes Oy Solution stable enzyme composition

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5597799A (en) 1990-09-04 1997-01-28 Cor Therapeutics, Inc. Recombinant agents affecting thrombosis
AT405517B (de) 1997-02-27 1999-09-27 Immuno Ag Faktor x-deletionsmutanten und analoge davon
AT405516B (de) 1997-02-27 1999-09-27 Immuno Ag Faktor x-analoge mit modifizierter proteasespaltstelle
AT410216B (de) 1999-08-10 2003-03-25 Baxter Ag Faktor x-analogon mit verbesserter aktivierbarkeit
AU2001249389A1 (en) 2000-03-22 2001-10-03 The Children's Hospital Of Philadelphia Modified blood clotting factors and methods of use
FR2831170B1 (fr) 2001-10-19 2004-03-19 Inst Nat Sante Rech Med Proteines c modifiees activables directement par la thrombine
FR2841904B1 (fr) 2002-07-03 2004-08-20 Inst Nat Sante Rech Med Analogues de facteurs x clivables par la thrombine
DK1781782T3 (da) 2004-08-17 2010-08-23 Csl Behring Gmbh Modificerede vitamin K-afhængige polypeptider
EP1728798A1 (en) 2005-06-01 2006-12-06 ZLB Behring GmbH Coagulation factor X polypeptides with modified activation properties
MX336958B (es) * 2005-11-15 2016-02-05 Philadelphia Children Hospital Metodos y composiciones para modular la hemostasia.
EP1820508A1 (en) 2006-02-21 2007-08-22 CSL Behring GmbH Coagulation factor X polypeptides with modified activation properties
KR102069498B1 (ko) * 2007-09-28 2020-01-23 포톨라 파마슈티컬스, 인코포레이티드 인자 Xa 저해제에 대한 안티도트 및 그것을 사용하는 방법
PL2300497T3 (pl) 2008-06-24 2013-02-28 Octapharma Ag Sposób oczyszczania czynnika krzepnięcia VIII
US8455439B2 (en) 2008-11-14 2013-06-04 Portola Pharmaceuticals, Inc. Antidotes for factor Xa inhibitors and methods of using the same in combination with blood coagulating agents
KR20110114587A (ko) 2008-12-19 2011-10-19 인쎄름 (엥스띠뛰 나씨오날 드 라 쌍떼 에 드 라 흐쉐르슈 메디깔) 세린 프로테아제 유도체 및 혈액응고 장애의 치료 또는 예방의 용도
ES2605801T3 (es) 2009-07-15 2017-03-16 Portola Pharmaceuticals, Inc. Formulación de dosis unitaria de antídoto para inhibidores del factor Xa para su uso en la prevención de la hemorragia
SI2591006T1 (sl) * 2010-07-09 2019-10-30 Bioverativ Therapeutics Inc Enoverižne molekule, ki jih lahko obdelujemo in polipeptidi izdelani z njihovo uporabo
FR2972114B1 (fr) 2011-03-01 2013-03-15 Univ Grenoble 1 Un nouveau leurre moleculaire procoagulant pour le traitement des hemophiles a ou b avec ou sans inhibiteur
EP2760887B1 (en) 2011-09-30 2024-10-23 The Children's Hospital of Philadelphia Compositions and methods for modulating hemostasis
CN104755492A (zh) 2012-07-25 2015-07-01 催化剂生物科学公司 修饰的因子x多肽及其应用
US20150343034A1 (en) 2013-01-31 2015-12-03 Pfizer Inc. Compositions and methods for counteracting factor xa inhibition
CN105579468A (zh) 2013-09-24 2016-05-11 辉瑞大药厂 包含重组人凝血因子Xa蛋白的异质性群体的组合物
WO2015066606A2 (en) 2013-11-01 2015-05-07 The Children's Hospital Of Philadelphia Compositions and methods for increasing the half-life of factor xa
PT3096779T (pt) 2014-01-24 2020-02-21 Pfizer Composições e métodos para tratamento de hemorragia intracerebral

Also Published As

Publication number Publication date
MY173548A (en) 2020-02-04
HK1218760A1 (zh) 2017-03-10
IL244258A0 (en) 2016-04-21
US9757434B2 (en) 2017-09-12
US20210106658A1 (en) 2021-04-15
AU2014326257B2 (en) 2017-08-10
CN112195169A (zh) 2021-01-08
US10660946B2 (en) 2020-05-26
KR20160044034A (ko) 2016-04-22
IL279396A (en) 2021-01-31
BR112016005899A2 (pt) 2017-09-26
CN105579468A (zh) 2016-05-11
TW201524996A (zh) 2015-07-01
PE20160877A1 (es) 2016-09-11
MX373466B (es) 2020-05-25
BR112016005899A8 (pt) 2018-02-06
TWI631134B (zh) 2018-08-01
CA2924981A1 (en) 2015-04-02
US20150182604A1 (en) 2015-07-02
AU2014326257A1 (en) 2016-03-10
SA516370751B1 (ar) 2018-04-05
MX2016003871A (es) 2016-08-04
KR101988705B1 (ko) 2019-06-12
EP3049434A1 (en) 2016-08-03
JP6429885B2 (ja) 2018-11-28
RU2648144C2 (ru) 2018-03-22
SG11201601221XA (en) 2016-04-28
WO2015044836A1 (en) 2015-04-02
RU2016108608A (ru) 2017-10-26
US20170333535A1 (en) 2017-11-23
JP2016535071A (ja) 2016-11-10
CA2924981C (en) 2020-03-31

Similar Documents

Publication Publication Date Title
CY1126072T1 (el) Περιοχες gla ως θεραπευτικοι παραγοντες
MX2017010734A (es) Terapia de combinacion con factores de coagulacion y anticuepos multiespecificos.
MX2018006745A (es) Metodos de tratamiento de neoplasias malignas.
DK3377637T3 (da) Sammensætninger til anvendelse i fremgangsmåder til behandling af sår, lidelser og sygdomme i huden
MX2015009058A (es) Composiciones y metodos para tratar la inflamacion cronica y las enfermedades inflamatorias.
SV2018005714A (es) Composiciones y metodos para disminuir la expresion de tau
IL257986B (en) Expression of recombinant proteins in trichoplusia ni pupae
MX2015003701A (es) Composiciones para tratamiento.
AR097732A1 (es) Composiciones que comprenden poblaciones heterogéneas de proteínas recombinantes humanas de factor xa de coagulación
UA117933C2 (uk) Поліпептид, здатний зв'язувати с5-компонент комплементу людини
EA201690855A1 (ru) Эндоглиновые пептиды для лечения фиброзных заболеваний
EP3634460A4 (en) S-NITROSOGLUTATHIOMA (GSNO) AND REDUCTASE INHIBITORS FOR USE IN THERAPY
CY1121000T1 (el) Sirna και χρηση αυτου σε μεθοδους και συνθεσεις για την θεραπεια ή/και προληψη οφθαλμικων καταστασεων
HUE054330T2 (hu) Graft versus host betegség kezelése transzplantációs betegekben
MX2019005693A (es) Factor viii direccionado a los globulos rojos y metodo para su uso.
MX380585B (es) Polipeptidos del factor vii de acción corta.
MX2015014265A (es) Combinacion sinergica de alanina-glutamina, acido hialuronico y un extracto de avena y su uso en una composicion destinada para la curacion de heridas y reparacion de lesiones de la piel.
MX2015011418A (es) Tratamiento de enfermedades con nanofibras de poli-n-acetilglucosamina.
EP3542808C0 (en) THERAPEUTIC VIRAL MICROPARTICLES TO PROMOTE STENT BIOFUNCTIONALITY AND HEALING IN VERTEBRATE INDIVIDUALS
EA201692161A1 (ru) Прогемостатические белки для лечения кровотечений
PH12014501044A1 (en) Methods for improved wound closure employing olivamine and human umbilical vien endothelial cells
PH12016500509A1 (en) Compositions comprising heterogeneous populations of recombinant human clotting factor xa proteins
MX385558B (es) Péptidos y métodos de uso.
EA201501176A1 (ru) Замещенные бензоксазолы
MX2015000983A (es) Composiciones antitranspirantes y metodos.

Legal Events

Date Code Title Description
FB Suspension of granting procedure